{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:00:42Z","timestamp":1794589242911,"version":"4.9.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes and Vascular Disease Research"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Evaluate the effect of sotagliflozin, a dual inhibitor of sodium glucose cotransporter (SGLT) 1 and 2, on arterial stiffness in patients with type 1 diabetes (T1D) treated with sotagliflozin as adjunct to optimized insulin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this post hoc analysis, indirect markers of arterial stiffness, including pulse pressure, mean arterial pressure (MAP), and double product, were calculated using observed systolic blood pressure (SBP), diastolic blood pressure (DBP), or pulse rate at 24\u2009weeks using data from a pooled patient population from the inTandem1 and inTandem2 randomized controlled trials ( n\u2009=\u20091575).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Baseline characteristics were similar among groups. Relative to placebo at Week 24, sotagliflozin 200\u2009mg and 400\u2009mg reduced SBP by 2.03\u2009mm Hg (95% CI \u22123.30 to \u22120.75; p\u2009=\u20090.0019) and 2.85\u2009mm Hg (\u22124.12 to \u22121.57; p\u2009&lt;\u20090.0001), respectively. DBP decreased by 1.1 and 0.9\u2009mm Hg, MAP by 1.4 and 1.6\u2009mm Hg, and double product by 202.5 and 221.1\u2009bpm\u2009\u00d7\u2009mm Hg, respectively ( p\u2009&lt;\u20090.05 for all). No increases in heart rate were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In adults with T1D, adding sotagliflozin to insulin significantly reduced blood pressure and other markers of arterial stiffness and vascular resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1479164121995928","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T04:17:22Z","timestamp":1613794642000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-8445","authenticated-orcid":false,"given":"Helena W","family":"Rodbard","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Consultants, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giaccari","sequence":"additional","affiliation":[{"name":"Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"L\u2019institut du thorax, UNIV Nantes, CNRS Inserm, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Garg","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Davies","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA"},{"name":"Esperion Therapeutics, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiernan","family":"Seth","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Sawhney","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA"},{"name":"Immuvant, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"bibr1-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"bibr2-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa015"},{"key":"bibr3-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.11.016"},{"key":"bibr4-1479164121995928","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.301"},{"key":"bibr5-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220206"},{"key":"bibr6-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.12.005"},{"key":"bibr7-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12572"},{"key":"bibr8-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0511-0"},{"key":"bibr9-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0797-6"},{"key":"bibr10-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-28"},{"key":"bibr11-1479164121995928","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0343"},{"key":"bibr12-1479164121995928","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0342"},{"key":"bibr13-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"bibr14-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"bibr15-1479164121995928","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13648"},{"key":"bibr16-1479164121995928","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2149"}],"container-title":["Diabetes and Vascular Disease Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1479164121995928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1479164121995928","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1479164121995928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:19:39Z","timestamp":1777400379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1479164121995928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1479164121995928"],"URL":"https:\/\/doi.org\/10.1177\/1479164121995928","relation":{},"ISSN":["1479-1641","1752-8984"],"issn-type":[{"value":"1479-1641","type":"print"},{"value":"1752-8984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"1479164121995928"}}